- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.10. | Ernexa Therapeutics Inc.: Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series | 1 | GlobeNewswire (USA) | ||
| 01.10. | Ernexa Therapeutics Inc.: Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic | 3 | GlobeNewswire (USA) | ||
| 30.09. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND | 294 | GlobeNewswire (Europe) | Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed... ► Artikel lesen | |
| 29.09. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy | 1 | GlobeNewswire (USA) | ||
| 17.09. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors | 191 | GlobeNewswire (Europe) | Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics Appointment... ► Artikel lesen | |
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 16.09. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.09. | Ernexa reports preclinical data for ERNA-201, refocuses on oncology | 1 | Investing.com | ||
| 15.09. | Ernexa meldet präklinische Daten für ERNA-201 und legt Fokus auf Onkologie | 2 | Investing.com Deutsch | ||
| 15.09. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing | 313 | GlobeNewswire (Europe) | ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC... ► Artikel lesen | |
| 10.08. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage | 1.158 | GlobeNewswire (Europe) | Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance Appointment further... ► Artikel lesen | |
| 06.08. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 24.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies | 1 | GlobeNewswire (USA) | ||
| 15.07. | Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy | 1 | Benzinga.com | ||
| 15.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry | 322 | GlobeNewswire (Europe) | Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND ERNA-101 Plus Anti-PD-1 Achieved... ► Artikel lesen | |
| 14.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 | 1 | GlobeNewswire (USA) | ||
| 26.06. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients | 1 | GlobeNewswire (USA) | ||
| 17.06. | Ernexa treibt Zelltherapie voran: Klinische Studie für dieses Jahr geplant | 3 | Investing.com Deutsch | ||
| 17.06. | Ernexa advances cell therapy toward clinical trial this year | 3 | Investing.com |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,050 | +0,66 % | Biofrontera AG: FDA-Zulassung - was jetzt folgt | ||
| DEFENCE THERAPEUTICS | 0,241 | +1,69 % | Defence Therapeutics Inc.: Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform | Montreal, Quebec--(Newsfile Corp. - October 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| TRAWS PHARMA | 0,380 | +1,01 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| CURIS | 0,364 | +3,09 % | CURIS INC - 8-K, Current Report | ||
| GENPREX | 2,050 | 0,00 % | Genprex highlights preclinical study on TUSC2 gene in brain aging | ||
| TVARDI THERAPEUTICS | 0,750 | -10,18 % | Tvardi auf Chardan Healthcare Conference: Neue Daten nähren Hoffnungen für STAT3-Plattform | ||
| NEOVACS | 0,101 | +4.950 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 22.10.2026 | Das Instrument 1DD FR001400H2X4 TONNER DRON. S.A.EO-,0001 EQUITY wird ex Kapitalmassnahme gehandelt am 22.10.2026 The instrument 1DD FR001400H2X4 TONNER DRON. S.A.EO-,0001 EQUITY is traded ex capital... ► Artikel lesen | |
| ALAUNOS THERAPEUTICS | 3,070 | -0,32 % | Alaunos Therapeutics, Inc. - 8-K, Current Report | ||
| MARKER THERAPEUTICS | 0,855 | -11,86 % | Marker Therapeutics sichert sich FDA-Förderung über 2,6 Millionen US-Dollar für Krebsstudie | ||
| AINOS | 0,880 | +0,01 % | Ainos, Inc. - 8-K, Current Report | ||
| MATINAS BIOPHARMA | 1,590 | +2,58 % | XFRA 6LJ: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMATINA.BIOPHA. O.N.... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,510 | 0,00 % | Enveric completes drug absorption studies for EB-003 candidate | ||
| NEUPHORIA THERAPEUTICS | 3,495 | +0,43 % | Neuphoria Therapeutics, Inc.: Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria"... ► Artikel lesen | |
| SCINAI IMMUNOTHERAPEUTICS LTD | 0,596 | -2,39 % | Scinai Immunotherapeutics Ltd.: Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing | Management estimates operating runway to late 2027, with potential extension into the third quarter of 2028 as later project phases under the recently announced CDMO agreement are activated... ► Artikel lesen | |
| CLEARMIND MEDICINE | 6,040 | +1,68 % | Clearmind Medicine Inc. - 6-K, Report of foreign issuer |
ERNEXA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,100 Euro und damit -0,47 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.